NCT07431255Not yet recruiting
Generation of Synthetic [18F]FDG PET From Early-Phase Amyloid PET in Alzheimer's Disease
Source: ClinicalTrials.gov · Last updated 24 Feb 2026
Brief summary (registry, in English)
This study aims to test a new artificial intelligence (AI) method to create brain scan images without needing an extra scan. Currently, patients with memory problems often undergo two types of PET scans (Amyloid PET and FDG PET) to assess Alzheimer's disease. This study will use existing scan data from patients who already had both scans as part of their routine care. The AI model will try to generate the FDG PET image using only the Amyloid PET scan and an MRI. If successful, this method could reduce radiation exposure, costs, and time for future patients by eliminating the need for a separate FDG injection and scan. No new scans, injections, or procedures will be performed for this study. All data will be fully anonymized (personal information removed) before analysis. The study involves approximately 35 adult patients (age 50+) whose data were collected between January 2025 and December 2025 at IRCCS Ospedale San Raffaele in Milan, Italy.
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 35 (estimated)
- First submitted
- 18 Feb 2026
- Start date
- 1 Mar 2026
- Primary completion date
- 31 Dec 2026
- Lead sponsor
- IRCCS San Raffaele
- Diseases
- Alzheimer disease
- NCT number
- NCT07431255
What you commit to
- Study type: Observational
- Planned participants: 35
- From 1 Mar 2026 to the primary completion date, 31 Dec 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Presence of other major neurological disorders that may confound FDG metabolism (e.g., Parkinson's disease, frontotemporal dementia, brain tumor, or recent stroke).
Other
- Severe motion artifacts or technical failures in any of the three imaging modalities that prevent reliable co-registration or SUVR calculation.
- Incomplete or irreversibly corrupted DICOM data preventing anonymization or conversion to analysis-ready format.
Who the study is looking for
- Age ≥ 50 years at the time of imaging.
- Clinically indicated amyloid PET scan performed with Florbetaben or Flutemetamol between January 1, 2025 and December 31, 2025.
- Availability of paired structural MRI (3D T1-weighted) and real \[18F\]FDG PET scan acquired within ±6 months of the amyloid PET.
- All three imaging modalities (Amyloid PET, FDG PET, MRI) are of sufficient technical quality for co-registration and quantitative analysis.
Age in the registry: 50 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| IRCCS Ospedale San Raffaele Coordinator of this site? Confirm its status | Milan | Italy | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.